.png){kind=small}
Shield ™ Early CRC Detection
Shield™ early colorectal cancer screening is a non-invasive blood test that allows for early detection of colorectal cancer. It utilizes a multimodal approach, integrating genomics, epigenomics, and proteomics, to provide highly sensitive and specific detection of early signs of colorectal cancer in average-risk adults aged 45 and above.
Guardant Health is a leading precision oncology company in the United States that has developed the first FDA-approved blood test for comprehensive genomic analysis of all solid tumors.
- Colorectal cancer (CRC) remains the second leading cause of cancer-related deaths in the United States.
- Approximately 150,000 people are diagnosed with colorectal cancer in the United States each year.
- Cancer screening is an effective method for detecting colorectal cancer early, when it is most treatable.
- Over 75% of individuals who died from colorectal cancer between 2006 and 2012 were not regularly screened. The 5-year survival rate improves significantly when colorectal cancer is detected at an early stage:Early stage (I-II): 90%
Late stage (IV): 14%
The Shield test employs a multimodal approach, integrating genomics, epigenomics, and proteomics, to detect signals of colorectal cancer in the blood, including circulating tumor DNA (ctDNA) released by tumors.
In validation studies, Shield demonstrated a sensitivity of 91% for colorectal cancer and a sensitivity of 20% for advanced adenomas, with a specificity (true negative rate) of 92% in normal cases.
ECLIPSE is a registered study involving over 12,750 patients, aiming to further validate the effectiveness of this technology in detecting early signs of colorectal cancer in average-risk adults. The results are expected to be published in 2022.
Shield is a laboratory-developed test (LDT) designed to complement current recommended colorectal cancer screening methods rather than replace them.
References:
- Centers for Disease Control and Prevention. Use of Colorectal Cancer Screening. https://www.cdc.gov/cancer/colorectal/statistics/use-screening-tests-BRFSS.htm. Accessed May 1, 2022.
- Centers for Disease Control and Prevention. Cost-effectiveness of colorectal cancer interventions. Updated August 18, 2021. Accessed December 7, 2021. https://www.cdc.gov/chronicdisease/programs-impact/pop/colorectal-cancer.htm
- Liles EG, Coronado GD, Perrin N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: a randomized trial. Cancer Treat Res Comm. 2017;10:27-31. doi:10.1016/j.ctarc.2016.12.004
- Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med. 2005;20(11):989-995. doi:10.1111/j.1525-1497.2005.00164.x
- Parks P. Innovation in colorectal cancer screening - there has to be a better way. Am J Manag Care. Published October 9, 2017. Accessed September 17, 2021. https://www.ajmc.com/view/innovation-in-colorectal-cancer-screening-there-has-to-be-a-better-way
- American Society of Clinical Oncology. Colonoscopy. Cancer.net website. Updated December 2019. Accessed December 7, 2021. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/colonoscopy
- Proportion ranking LUNAR-2 as top CRC screening preference*, Overall N=299, GH Internal LUNAR2 Patient Research. www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html Accessed online Feb 5, 2021.
- Chakrabarti S, Peterson C, Sriram D, Amit Mahipal A, et al. Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World J Gastro Oncol. 2020 Aug 15; 12(8): 808–832.
- American Cancer Society: Colorectal Cancer Facts & Figured 2020-2022. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf. Accessed online Feb 5, 2021.
- Rich T, Raymond V, Lang K. Where are we today? Efforts to understand strategies and barriers to physician issuance of a recommendation for colorectal cancer screening: a systematic review. Gastroenterology. 2020;158(6 suppl 1): S-918. doi:10.1016/S0016-5085(20)32981-4.
- Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable failures in the colorectal cancer screening process and their association with risk of death. Gastroenterology. 2019;156(1):63-74. doi:10.1053/j.gastro.2018.09.040.
The expected turnaround time for this test report is 2 weeks.
Once your test report is ready, you will receive a notification from the clinic to schedule a collection and explanation appointment.
*Please note that currently, only an English version of the test report is available.
During the order confirmation process, the system will provide available appointment slots at different branches of the Hong Kong Health Screening Center. We will make a reservation for you based on your selected branch and time slot. If the chosen branch or time slot is not available for booking, our customer service representative will contact you to arrange an alternative branch or time slot.
On the day of the scheduled blood draw, please bring your original identification documents to the designated branch of the Hong Kong Health Screening Center for registration. The staff will assist you with the blood draw procedure.
After the blood draw is completed, our staff will collect the blood sample at the Hong Kong Health Screening Center branch and transport it to our laboratory. Please do not attempt to take the blood sample out of the Hong Kong Health Screening Center on your own.
Once our laboratory receives and confirms the quality of your saliva or blood sample meets the testing standards, you will receive an email notification, and you can track the testing progress on this online platform.
